GC
NAUT icon

Garde Capital’s Nautilus Biotechnolgy NAUT Stock Holding History

Garde Capital’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Hold
11,000
– – ﹤0.01% 246
2026
Q1 		$42.7K Sell
11,000
-7,000
-39% -$17.2K ﹤0.01% 198
2025
Q4 		$35.1K Buy
+18,000
New +$29.5K ﹤0.01% 212

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Garde Capital's NAUT Position: Q2 2026 in Review

Garde Capital held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 11,000 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #246.

Garde Capital first reported a position in NAUT in Q4 2025 and has held it in 3 quarters since. The position peaked at $42.7K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Garde Capital held 11,000 shares of Nautilus Biotechnolgy worth $20.6K as of Q2 2026.
  • Garde Capital left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Garde Capital's portfolio in Q2 2026, its #246 holding.
  • Garde Capital first reported a position in Nautilus Biotechnolgy in Q4 2025 and has held it in 3 quarters since.
  • Garde Capital's Nautilus Biotechnolgy position peaked at $42.7K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Garde Capital's 13F filing for Q2 2026, filed 31 Jul 2026.